Does this diabetes drug protect kidneys even if you're already on another kidney medicine?
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 587 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 587 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Journal
Diabetes Care
Year
2025
Authors
P. Rossing, G. Bakris, V. Perkovic, R. Pratley, K. Tuttle, Kenneth W Mahaffey, T. Idorn, Nicolas Belmar, H. Bosch‐Traberg, S. Rasmussen, Robert Busch, Roland E. Schmieder, Pieter Gillard, J. Mann
Related Content
Claims (6)
In people with type 2 diabetes and kidney disease, the medication semaglutide slows the decline in kidney function by about 1.2 mL/min/1.73m² per year compared to a placebo, as measured by standard blood markers.
In people with type 2 diabetes and kidney disease, a medication called semaglutide lowers a marker of kidney damage (urinary albumin-to-creatinine ratio) by about 30% after two years compared to a placebo, and this effect does not depend on whether they were already taking mineralocorticoid receptor antagonists.
For adults with type 2 diabetes and chronic kidney disease, taking semaglutide along with mineralocorticoid receptor antagonists does not lead to a meaningful increase in the risk of high blood potassium levels.
In patients with type 2 diabetes and chronic kidney disease, the medication semaglutide is associated with a lower chance of developing kidney failure and other kidney-related complications, even when accounting for changes in body weight.
In adults with type 2 diabetes and kidney disease, a weekly injection of semaglutide at 1.0 mg lowers the combined risk of severe kidney function decline, kidney failure, or death from kidney or heart causes by 24% compared to a placebo over about 3.4 years, regardless of whether they were already taking mineralocorticoid receptor antagonists.